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Abstract
The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of myeloma (MM) cells.
This study identified that microRNA-15a and -16 expressions tightly correlated with proliferation and drug sensitivity of
MM cells. miRNA-15a/-16 expression in MM cells was significantly increased after treatment with cytotoxic agents. The
interaction of bone marrow stromal cells (BMSC) with MM cells resulted in decreased miRNA-15a/-16 expression and
promoted the survival of the MM cells. Interleukin-6 (IL-6) produced by BMSCs suppressed the expression of miRNA-15a
and 16 in a time- and dose- dependent pattern, with the suppression on miRNA-15a being more significant than on
miRNA-16. miRNA-15a-transfected MM cells were found to be arrested in G1/S checkpoint, and the transfected MM
cells had decreased growth and survival. In conclusion, our data suggest that via suppressing miRNA-15a and -16
expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells.
To the Editor
Multiple myeloma (MM) is an incurable plasma cell
malignancy [1-3]. Binding of MM cells to bone marrow
stromal cells (BMSCs) promotes the growth, survival,
metastasis and drug resistance of the MM cells. The
molecular bases of MM progression and drug resistance
remain incompletely understood [4,5]. In this study,
apoptosis analysis by flow cytometry showed that
BMSCs protect U266 and NCI-H929 myeloma cells
from apoptosis induced by melphalan and bortezomib.
(Figure 1A). IL-6 and VEGF are critical growth factors
for myeloma cells. Both are mainly produced by BMSCs
[6-8]. By ELISA analysis, we found that the level of IL-6
and VEGF secreted in the supernatant of BMSCs
derived from MM patient (MM-BMSCs) was signifi-
cantly higher (188.8+9.4 pg/mL and 1497.2+39.7 pg/mL,
r e s p e c t i v e l y )t h a nt h a to fn o r m a lB M S C s( 1 1 5 . 0 + 1 5 . 1
pg/mL and 1239.0+21.1 pg/mL, respectively; p < 0.05).
microRNA -15a and -16 are located on chromosome
13, an area commonly deleted in MM. Deletion of chro-
mosome 13 predicts a significantly reduced survival in
patient with MM [9-11]. We thus focused on the func-
tions of miRNA-15a and -16. We found that miRNA-
15a/-16 expression in MM cells was significantly
increased under melphalan and bortezomib treatment
(Figure 1B). Moreover, dexamethasone sensitive MM
cell line, MM1S, expressed higher level of miRNA-15a
than the resistant MM1R. miRNA-15a expression in
MMIS and MM1R was 909.73 ± 7.12 and 134.88 ±
19.85 (p < 0.01), respectively, and miRNA-16 expression
in those cells was 9.83 ± 2.01 and 9.20 ± 3.81 (p > 0.05),
respectively. Interestingly, the interaction of MM cells
with MM-BMSCs inhibited miRNA-15a and -16 expres-
sions in MM cells. (Figure 1B) IL-6 secreted by MM-
BMSCs decreased expression of miRNA-15a and -16 in
myeloma cells in a time- and dose- dependent pattern.
(Figure 1C,D) The suppression on miRNA-15a was
more significant than on miRNA-16 in myeloma cells.
Previous study has identified cyclinD1, cyclinD2 and
CDC25A as the targets of miRNA-15a [12]. Our data
further showed that miRNA-15a-transfected MM cells
were arrested in G1/S checkpoint. The over-expression
of miRNA-15a inhibited growth and survival of the
transfected MM cells.
In conclusion, this study identified that microRNA-
15a and -16 expressions correlated well with prolifera-
tion and drug sensitivity of MM cells. MM-BMSCs
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them from drug-induced apoptosis by suppressing
miRNA-15a/-16 expression. IL-6 secreted by the MM-
BMSCs plays a pivotal role in this process.
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